Premium
Cell Membrane‐Camouflaged NIR II Fluorescent Ag 2 Te Quantum Dots‐Based Nanobioprobes for Enhanced In Vivo Homotypic Tumor Imaging
Author(s) -
Zhang JingJing,
Lin Yi,
Zhou Hui,
He He,
Ma JiaoJiao,
Luo MengYao,
Zhang ZhiLing,
Pang DaiWen
Publication year - 2019
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201900341
Subject(s) - fluorescence , in vivo , biocompatibility , materials science , biophysics , fluorescence lifetime imaging microscopy , membrane , quantum dot , cancer cell , nanotechnology , preclinical imaging , chemistry , cancer , optics , biochemistry , biology , physics , microbiology and biotechnology , genetics , metallurgy
The advantages of fluorescence bioimaging in the second near‐infrared (NIR II, 1000–1700 nm) window are well known; however, current NIR II fluorescent probes for in vivo tumor imaging still have many shortcomings, such as low fluorescence efficiency, unstable performance under in vivo environments, and inefficient enrichment at tumor sites. In this study, Ag 2 Te quantum dots (QDs) that emit light at a wavelength of 1300 nm are assembled with poly(lactic‐ co ‐glycolic acid) and further encapsulated within cancer cell membranes to overcome the shortcomings mentioned above. The as‐prepared ≈100 nm biomimetic nanobioprobes exhibit ultrabright (≈60 times greater than that of free Ag 2 Te QDs) and highly stable (≈97% maintenance after laser radiation for 1 h) fluorescence in the NIR II window. By combining the active homotypic tumor targeting capability derived from the source cell membrane with the passive enhanced permeation and retention effect, improved accumulation at tumor sites ((31 ± 2)% injection dose per gram of tumor) and a high tumor‐to‐normal tissue ratio (13.3 ± 0.7) are achieved. In summary, a new biomimetic NIR II fluorescent nanobioprobe with ultrabright and stable fluorescence, homotypic targeting and good biocompatibility for enhanced in vivo tumor imaging is developed in this study.